Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3

References

• Luana Y, Daib HL, Yangb D, Zhub L, Gaob TL, Shaob HJ, Pengb X, Jin ZF. Small interfering RNA against the 2C genomic region of Coxsackievirus B3 exerts potential antiviral effects in permissive HeLa cells. Virus Res J. 2012;163:183–189.
   PubMed Web of Science ®Google Scholar
• Riabi S, Gaaloul I, Harrath R, Aouni M. Persistent infection of human intestinal Caco-2 cell line by Coxsackieviruses B. Pathol Biol. 2012;60:347–351.
   PubMed Web of Science ®Google Scholar
• Wang T, Yu B, Lin L, Zhai X, Han Y, Qin Y, Guo Z, Wu S, Zhong X, Wang Y, Tong L, Zhang F, Si X, Zhao W, Zhong Z. A functional nuclear localization sequence in the VP1 capsid protein of Coxsackievirus B3. Virology. 2012;433:513–521.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao W, Xie YH, Yang Q, Li XQ, Liu XX, Wang SW. The comparison of α-bromo-4-chlorocinnamaldehyde and cinnamaldehyde on Coxsackie virus B3-induced myocarditis and their mechanisms. Int Immunopharmacol. 2012;14:107–113.
   PubMed Web of Science ®Google Scholar
• Chung SY, Cho YJ, Kim YJ, Kim DS, Lee H, Nam JH. Development of peptide antibody against Coxsackievirus B3 VP2. J Bacteriol Virol. 2006;36:109–117.
   Google Scholar
• Rassmann A, Henke A, Jarasch N, Lottspeich F, Saluz HP, Munder T. The human fatty acid synthase: a new therapeutic target for Coxsackievirus B3-induced diseases? Antivir Res. 2007;76:150–158.
   PubMed Web of Science ®Google Scholar
• Shim SH, Kim YJ, Kim DS, Nam JH. Development of a gene therapy method for cervical cancer using attenuated Coxsackievirus B3 as a vector system. J Bacteriol Virol. 2011;41:123–130.
   Google Scholar
• Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano G. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44:79–86.
   PubMed Web of Science ®Google Scholar
• Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A. A rapid assay for evaluation of antiviral activity against Coxsackievirus B3, Influenza virus A, and Herpes simplex virus type 1. J Virol Methods. 2001;95:133–143.
   PubMed Web of Science ®Google Scholar
• Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of Coxsackie B3 myocarditis with analysis of lymphocyte subsets. J Am Coll Cardiol. 1988;12:1334–1341.
   PubMed Web of Science ®Google Scholar
• Rezkalla Shereif H, Raikar Sharmishtha K, Robert A. Treatment of viral myocarditis with focus on captopril. Am J Cardiol. 1996;77:634–637.
   PubMed Web of Science ®Google Scholar
• Petros AM, Walter C, Lidija G, Effie T, Avrelija C. Lactic acid bacteria efficiently protect human and animal intestinal ephithelial and immune cells from enteric virus infection. Int J Food Microbiol. 2010;141:591–597.
   Google Scholar
• Colbère-Garapin F, Martin-Latil S, Blondel B, Mousson L, Pelletier I, Autret A, François A, Niborski V, Grompone G, Catonnet G, van de Moer A. Prevention and treatment of enteric viral infections: possible benefits of probiotic bacteria. Microbes Infect. 2007;9:1623–1631.
   PubMed Web of Science ®Google Scholar
• Botića T, Klingbergb TD, Weingartlc H, Cencič A. A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteria. Int J Food Microbiol. 2007;115:227–234.
   PubMed Web of Science ®Google Scholar
• Ivec M, Botić T, Koren S, Jakobsen M, Weingartl H, Cencic A. Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus. Antivir Res. 2007;75:266–274.
   PubMed Web of Science ®Google Scholar
• De Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, Schrezenmeir J. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine. 2006;24:6670–6674.
   PubMed Web of Science ®Google Scholar
• Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY, Lee HJ, Woo SH, Kim HM, Lee JB, Park SY, Choi IS, Song CS. Intranasal administration of live Lactobacillus species facilitates protection against Influenza virus infection in mice. Antivir Res. 2012;93:138–143.
   PubMed Web of Science ®Google Scholar
• An HM, Lee DK, Kim JR, Lee SW, Cha MK, Lee KO, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM 0214 against Herpes simplex virus type 1. Arch Pharm Res. 2012;35:1665–1671.
   PubMed Web of Science ®Google Scholar
• Yua Z, Huanga Z, Saob C, Huangb Y, Zhanga F, Yanga J, Liana J, Zenga Z, Luoc W, Zenga W, Denga Q. Bifidobacterium as an oral delivery carrier of Interleukin-12 for the treatment of Coxsackievirus B3-induced myocarditis in the Balb/c mice. Int Immunopharmacol. 2012;12:125–130.
   PubMed Web of Science ®Google Scholar
• Watkins RT, Woegerbauer M, Hollemann D, Hufnagl P. Rapid diagnosis of Enterovirus infections by real-time PCR on the LightCycler using the TaqMan format. Diagn Microbiol Infect Dis. 2002;42:99–105.
   PubMed Web of Science ®Google Scholar
• Krieg NR, Holt JG. In Bergey's manual of systematic bacteriology. Vol. 1. The Williams & Wilkins Co.; 1984. p. 1418–1434.
   Google Scholar
• Ahn JB. Isolation and characterization of Bifidobacterium producing exopolysaccharide. Food Eng Prog. 2005;9:291–296.
   Google Scholar
• Ahn JH, Jun ES, Lee HS, Yoon SY, Kim D, Joo CH, Kim YK, Lee H. A small interfering RNA targeting Coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol. 2005;79:8620–8624.
   PubMed Web of Science ®Google Scholar
• Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH. Rapid detection of Enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol. 2001;39:4093–4096.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Cha MK, Lee DK, An HM, Lee SW, Shin SH, Kwon JH, Kim KJ, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM1005-A on Human papillomavirus typeo 16. BMC Med. 2012;10:72. doi:10.1186/1741-7015-10-72
   PubMed Web of Science ®Google Scholar
• Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Bifidobacteria as probiotic agents- physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005;22:495–512.
   PubMed Web of Science ®Google Scholar
• Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, de Sousa JS, Sandhu B, Szajewska H, Weizman Z. Laclobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30:54–60.
   PubMed Web of Science ®Google Scholar
• Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Moller PL, Pedersen P, Tvede M, Weyrehter H, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis. 2002;21:411–416.
   Google Scholar
• Lee DK, Kang JY, Shin HS, Park IH, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM0212 against Hepatitis B virus. Arch Pharm Res. 2013;36(12):1525–1532. doi:10.1007/s12272-013-0141-3
   PubMed Web of Science ®Google Scholar
• Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559–568.
   PubMed Web of Science ®Google Scholar
• Chieux V, Chehadeh W, Harvey J, Haller O, Wattré P, Hober D. Inhibition of Coxsackievirus B4 replication in stably transfected cells expressing human MxA protein. Virology. 2001;283:84–92.
   PubMed Web of Science ®Google Scholar